Link Between Gene Mutation and Mental Illness
A group of physicians focused on genetics and neurology has found a significant connection between mental disorders, particularly schizophrenia, and mutations in the GRIN2A gene. They suggest that this discovery could pave the way for preventive treatments down the line.
The GRIN2A gene plays a vital role in neuron communication by generating the GluN2A protein. When it’s functioning well, this gene helps in transmitting electrical signals between nerve cells, which is crucial for essential functions like learning, memory, and brain development.
In their study published in Molecular Psychiatry, researchers showed that mutations in this gene hinder the activity of the NMDA receptor, which is key for neuronal communication, thus elevating the risk of developing mental health issues.
Out of 121 individuals examined, 85 had a variant of the GRIN2A gene, and 23 of those went on to develop a mental illness. This suggests that those with the mutation face a significantly higher risk compared to those without such variants. Moreover, the patients displayed purely psychiatric symptoms, which significantly diminishes the likelihood that environmental factors played a role.
This finding challenges the widely-held belief that mental disorders stem from multiple genetic factors. Clinicians have long believed that these conditions arise from a complex interplay of various influences. However, this study indicates for the first time that a single gene mutation can play a crucial role in the emergence of mental illness.
The report also references earlier studies that explored treating NMDA receptor deficiencies, linked to the GRIN2A mutation, with L-serine, an amino acid. In a trial with four schizophrenia patients, there were notable improvements: hallucinations disappeared, paranoia lessened, and overall behavior improved following treatment.
While this trial occurred before the primary study, the authors caution that it’s premature to classify it as a definitive treatment method. Nonetheless, they believe the effectiveness of L-serine warrants further investigation through randomized, double-blind clinical trials.
Schizophrenia’s Ongoing Mysteries
Schizophrenia presents with symptoms like delusions, hallucinations, disorganized thinking, and behavioral changes, alongside loss of motivation or enjoyment. The World Health Organization (WHO) estimates that about 23 million people globally suffer from this disorder, amounting to 0.29 percent of the world population. For adults, the prevalence increases to 0.43 percent, which translates to approximately 1 in every 233 people.
Experts have a solid grasp of its symptoms and know the typical age ranges for onset. There are effective treatments available, and several recognized risk factors, including genetic predispositions, neurochemistry, and external stresses like drug use.
Yet, a singular cause remains elusive, and the variability in who develops the illness versus who does not—especially among those with a family history—is still a mystery. Strategies for preventing schizophrenia’s onset are, as of now, not clearly defined.
